{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:07:47Z","timestamp":1772168867046,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/f1000research.135252.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000}}],"reference-count":74,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>Background Gynecologic cancer is a significant public health concern worldwide, with three of the top ten most common cancers affecting women. The increasing incidence of deep vein thrombosis (DVT) and the disproportionately poor outcomes in cancer patients necessitates urgent intervention. This study aimed to analyze the factors affecting the survivability of cancer patients with DVT, especially among gynecologic and non-gynecologic cancers. Methods An ambispective cohort study was conducted among gynecologic and non-gynecologic cancer patients with DVT, from January 2011 until August 2013. All subjects were observed for three months. The presence of DVT was confirmed using Doppler ultrasound. The analysis was performed using Kaplan-Meier survival analysis. The statistical significance was determined using the log-rank\/Mantel-Cox test. Results Among 223 cancer subjects with DVT, 61.4% of the subjects developed short-term mortality. In the overall group, the survival time was significantly lower in subjects who developed immobilization status (p-value &lt;0.001), advanced cancer stages (p-value &lt;0.045), and infection status (p-value &lt;0.001). In the gynecologic cancer group, the survival time was significantly lower in subjects who developed immobilization (p-value 0.007) and infection status (p-value 0.021). In the non-gynecologic cancer group, the survival time was significantly lower in subjects who developed immobilization (p-value 0.008), infection (p-value 0.002), undergo cancer surgery (p-value 0.024), and received high-risk systemic therapy (p-value 0.048). Additionally, the most common infection was pneumonia (29.6%). Conclusions Both gynecologic and non-gynecologic cancer patients who experienced DVT developed a high short-term mortality. Our finding of immobility, infection, advanced cancer stages, systemic therapy, and cancer surgery as risk factors that affect the survivability highlights the necessity of administering secondary prophylaxis as a standard procedure in clinical practice.<\/ns3:p>","DOI":"10.12688\/f1000research.135252.2","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T10:10:16Z","timestamp":1702375816000},"page":"890","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The factors affecting the survivability of malignant cancer patients with deep vein thrombosis among subjects with gynecologic and non-gynecologic\u00a0cancer: An ambispective cohort study"],"prefix":"10.12688","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3246-3352","authenticated-orcid":false,"given":"Andhika","family":"Rachman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Griskalia","family":"Christine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachelle","family":"Betsy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Juanputra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8363-068X","authenticated-orcid":false,"given":"Widya","family":"Pratiwi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"446-456","DOI":"10.1007\/s11239-012-0741-7","article-title":"Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database study.","volume":"34","author":"H Huang","year":"2012 Nov 13","journal-title":"J. Thromb. Thrombolysis."},{"key":"ref2","article-title":"Worldwide cancer data.","year":"2022. cited 2023 May 16"},{"key":"ref3","article-title":"Summary statistic 2020.","year":"2020. cited 2023 May 16"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"651-657","DOI":"10.1089\/jwh.2013.4465","article-title":"Gynecologic Cancer Prevention and Control in the National Comprehensive Cancer Control Program: Progress, Current Activities, and Future Directions.","volume":"22","author":"S Stewart","year":"2013 Aug","journal-title":"J. Womens Health."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"620-624","DOI":"10.1016\/j.ygyno.2012.08.038","article-title":"Five-year trends in mortality indices among gynecological cancer patients in Canada.","volume":"127","author":"N Akhtar-Danesh","year":"2012 Dec","journal-title":"Gynecol. Oncol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"287-299","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: epidemiology and risk factors.","volume":"11","author":"Z Momenimovahed","year":"2019 Apr","journal-title":"Int. J. Women\u2019s Health."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"720-728","DOI":"10.21147\/j.issn.1000-9604.2020.06.05","article-title":"Cervical cancer: Epidemiology, risk factors and screening.","volume":"32","author":"S Zhang","year":"2020","journal-title":"Chin. J. Cancer Res."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.3390\/cancers13112623","article-title":"New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO\/ESTRO\/ESP Guidelines.","volume":"13","author":"A Santoro","year":"2021 May 26","journal-title":"Cancers (Basel)."},{"key":"ref9","article-title":"Uterine Cancer. StatPearls.","author":"U Faizan","year":"2023 cited 2023 May 16"},{"key":"ref10","article-title":"Endometrial Cancer. StatPearls.","author":"H Mahdy","year":"2023 cited 2023 May 16"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4102\/sajid.v37i1.359","article-title":"Vitamin D status and COVID-19 severity.","volume":"37","author":"S Kalichuran","year":"2022 Apr 26","journal-title":"S. Afr. J. Infect. Dis."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"174-182","DOI":"10.3802\/jgo.2014.25.3.174","article-title":"Trends in gynecologic cancer mortality in East Asian regions.","volume":"25","author":"J Lee","year":"2014","journal-title":"J. Gynecol. Oncol."},{"key":"ref13","first-page":"693-696","article-title":"Deep vein thrombosis in primary care: possible malignancy?","volume":"56","author":"R Oudega","year":"2006 Sep","journal-title":"Br. J. Gen. Pract."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e14722","DOI":"10.5812\/ircmj.14722","article-title":"The Association of Deep Vein Thrombosis With Cancer Treatment Modality: Chemotherapy or Surgery?","volume":"16","author":"M Samare Fekri","year":"2014 Sep 5","journal-title":"Iran. Red Crescent Med. J."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"648-655","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.","volume":"119","author":"A Khorana","year":"2013 Feb 1","journal-title":"Cancer."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"S30-S34","DOI":"10.1016\/S0049-3848(09)70140-9","article-title":"Pathophysiology of venous thrombosis.","volume":"123","author":"J L\u00f3pez","year":"2009 Jan","journal-title":"Thromb. Res."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"469-481","DOI":"10.2146\/ajhp110187","article-title":"Preventing venous thromboembolism in hospitalized patients with cancer: Improving compliance with clinical practice guidelines.","volume":"69","author":"A Brown","year":"2012 Mar 15","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.669288","article-title":"Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review.","volume":"8","author":"L Lee","year":"2021 May 21","journal-title":"Front. Cardiovasc. Med."},{"key":"ref19","first-page":"131-138","article-title":"Factors affecting survival of women diagnosed with breast cancer in El-Minia Governorate, Egypt.","volume":"2","author":"A Seedhom","year":"2011 Jul","journal-title":"Int. J. Prev. Med."},{"key":"ref20","first-page":"293-300","article-title":"Recurrent venous thromboembolism.","volume":"83","author":"N Galioto","year":"2011 Feb 1","journal-title":"Am. Fam. Physician."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"585-593","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the Incidence of Deep Vein Thrombosis and Pulmonary Embolism.","volume":"158","author":"M Silverstein","year":"1998 Mar 23","journal-title":"Arch. Intern. Med."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1950-1956","DOI":"10.1111\/j.1538-7836.2006.02082.x","article-title":"Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry.","volume":"4","author":"M Monreal","year":"2006 Sep","journal-title":"J. Thromb. Haemost."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1186\/s12885-017-3719-1","article-title":"Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis.","volume":"17","author":"U Khan","year":"2017 Dec 10","journal-title":"BMC Cancer."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"24-30","DOI":"10.1016\/j.thromres.2012.10.007","article-title":"Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry.","volume":"131","author":"G Gussoni","year":"2013 Jan","journal-title":"Thromb. Res."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13017-016-0078-1","article-title":"Wells criteria for DVT is a reliable clinical tool to assess the risk of deep venous thrombosis in trauma patients.","volume":"11","author":"S Modi","year":"2016 Dec 8","journal-title":"World J. Emerg. Surg."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"297-303","DOI":"10.1093\/annonc\/mdj068","article-title":"Risk factors for venous thromboembolic events in cancer patients.","volume":"17","author":"K Kr\u00f6ger","year":"2006 Feb","journal-title":"Ann. Oncol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"286-294","DOI":"10.1200\/JCO.1991.9.2.286","article-title":"Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.","volume":"9","author":"T Saphner","year":"1991 Feb","journal-title":"J. Clin. Oncol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"60-62","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer.","volume":"365","author":"A Howell","year":"2005 Jan","journal-title":"Lancet."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"492-494","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.","volume":"98","author":"B Barlogie","year":"2001 Jul 15","journal-title":"Blood."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"431-436","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group.","volume":"24","author":"S Rajkumar","year":"2006 Jan 20","journal-title":"J. Clin. Oncol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2272-2272","DOI":"10.1182\/blood-2002-06-1674","article-title":"Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.","volume":"100","author":"M Cavo","year":"2002 Sep 15","journal-title":"Blood."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1614-1615","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.","volume":"98","author":"M Zangari","year":"2001 Sep 1","journal-title":"Blood."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2574-2576","DOI":"10.1200\/JCO.2005.81.908","article-title":"Thromboembolic Events in Gastric Cancer: High Incidence in Patients Receiving Irinotecan- and Bevacizumab-Based Therapy.","volume":"23","author":"M Shah","year":"2005 Apr 10","journal-title":"J. Clin. Oncol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2335-2342","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer.","volume":"350","author":"H Hurwitz","year":"2004 Jun 3","journal-title":"N. Engl. J. Med."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"132-135","DOI":"10.1200\/JCO.2009.23.0169","article-title":"Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone.","volume":"28","author":"M Zangari","year":"2010 Jan 1","journal-title":"J. Clin. Oncol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"708-714","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients.","volume":"98","author":"J Bohlius","year":"2006 May 17","journal-title":"J. Natl. Cancer Inst."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"914-924","DOI":"10.1001\/jama.299.8.914","article-title":"Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia.","volume":"299","author":"C Bennett","year":"2008 Feb 27","journal-title":"JAMA."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2506-2514","DOI":"10.1182\/blood.V93.8.2506","article-title":"Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor.","volume":"93","author":"A Falanga","year":"1999 Apr 15","journal-title":"Blood."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"675-681","DOI":"10.1089\/15258160260194820","article-title":"Induction of a Hypercoagulability State and Endothelial Cell Activation by Granulocyte Colony-Stimulating Factor in Peripheral Blood Stem Cell Donors.","volume":"11","author":"M Canales","year":"2002 Aug","journal-title":"J. Hematother. Stem Cell Res."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"655-662","DOI":"10.1160\/TH10-08-0530","article-title":"Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration.","volume":"105","author":"A Spiel","year":"2011 Nov 28","journal-title":"Thromb. Haemost."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"89-95","DOI":"10.1097\/01.sla.0000193959.44677.48","article-title":"A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery.","volume":"243","author":"G Agnelli","year":"2006 Jan","journal-title":"Ann. Surg."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"871-873","DOI":"10.1046\/j.1365-2141.2003.04515.x","article-title":"Falsely elevated D-dimer results in a healthy patient on account of heterophiletul antibodies.","volume":"122","author":"C Gardiner","year":"2003 Sep","journal-title":"Br. J. Haematol."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"490-493","DOI":"10.1016\/j.thromres.2009.12.023","article-title":"Venous thromboembolism and prognosis in cancer.","volume":"125","author":"A Khorana","year":"2010 Jun","journal-title":"Thromb. Res."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"632-634","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.","volume":"5","author":"A Khorana","year":"2007 Mar","journal-title":"J. Thromb. Haemost."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1752-1760","DOI":"10.1111\/j.1538-7836.2012.04829.x","article-title":"Influence of recent immobilization and recent surgery on mortality in patients with pulmonary embolism.","volume":"10","author":"D Nauffal","year":"2012 Sep","journal-title":"J. Thromb. Haemost."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"62-69","DOI":"10.1053\/j.seminhematol.2007.02.004","article-title":"Epidemiology and risk factors for venous thrombosis.","volume":"44","author":"M Cushman","year":"2007 Apr","journal-title":"Semin. Hematol."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"225-229","DOI":"10.1016\/j.blre.2009.07.002","article-title":"Basic mechanisms and pathogenesis of venous thrombosis.","volume":"23","author":"C Esmon","year":"2009 Sep","journal-title":"Blood Rev."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"143-166","DOI":"10.2522\/ptj.20150264","article-title":"Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline.","volume":"96","author":"E Hillegass","year":"2016 Feb 1","journal-title":"Phys. Ther."},{"key":"ref49","article-title":"Early Mobilization for Patients with Venous Thromboembolism: A Review of Clinical Effectiveness and Guidelines.","author":"V Chatsis","year":"2018 cited 2023 May 16"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"290-315","DOI":"10.3747\/co.24.3619","article-title":"Exercise for People with Cancer: A Systematic Review.","volume":"24","author":"R Segal","year":"2017 Aug 1","journal-title":"Curr. Oncol."},{"key":"ref51","first-page":"685-687","article-title":"Cancer staging and survival rates: an analysis.","volume":"8","author":"R Spencer","year":"1988","journal-title":"Anticancer Res."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"67-71","DOI":"10.1006\/gyno.2001.6452","article-title":"The Clinical Course of Deep Vein Thrombosis in Patients with Gynecologic Cancer.","volume":"84","author":"M Morgan","year":"2002 Jan","journal-title":"Gynecol. Oncol."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2465-2474","DOI":"10.1007\/s11033-021-07020-6","article-title":"Neutralizing antibody: a savior in the Covid-19 disease.","volume":"49","author":"S Gupta","year":"2022 Mar 6","journal-title":"Mol. Biol. Rep."},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2016.ed61","article-title":"The principles of cancer staging.","volume":"10","author":"J Brierley","year":"2016 Nov 24","journal-title":"Ecancermedicalscience."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/healthcare8010048","article-title":"Predictive Factors of Deep Vein Thrombosis in Gynecologic Cancer Survivors with Lower Extremity Edema: A Single-Center and Retrospective Study.","volume":"8","author":"J Kim","year":"2020 Feb 27","journal-title":"Healthcare."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay9040","article-title":"Early detection of cancer.","volume":"375","author":"D Crosby","year":"2022 Mar 18","journal-title":"Science (1979)."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"871-895","DOI":"10.1007\/s40121-021-00433-7","article-title":"Fatal Infections Among Cancer Patients: A Population-Based Study in the United States.","volume":"10","author":"Y Zheng","year":"2021 Jun 24","journal-title":"Infect. Dis. Ther."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13027-021-00413-z","article-title":"Infectious diseases as a cause of death among cancer patients: a trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database.","volume":"16","author":"M Elhadi","year":"2021 Dec 31","journal-title":"Infect. Agent Cancer."},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1620-1628","DOI":"10.1016\/j.jtcvs.2018.10.140","article-title":"Survival benefits associated with surgery for advanced non\u2013small cell lung cancer.","volume":"157","author":"E David","year":"2019 Apr","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"326-343","DOI":"10.1097\/01.sla.0000179621.33268.83","article-title":"Determinants of Long-Term Survival After Major Surgery and the Adverse Effect of Postoperative Complications.","volume":"242","author":"S Khuri","year":"2005 Sep","journal-title":"Ann. Surg."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/cancers13051033","article-title":"Association between Radiotherapy and Risk of Cancer Associated Venous Thromboembolism: A Sub-Analysis of the COMPASS\u2014CAT Study.","volume":"13","author":"S Temraz","year":"2021 Mar 2","journal-title":"Cancers (Basel)."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1026-1031","DOI":"10.1016\/j.ijrobp.2017.01.218","article-title":"Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events.","volume":"97","author":"C Bosco","year":"2017 Apr","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1753-1762","DOI":"10.1002\/cam4.4559","article-title":"Venous thromboembolism and radiation therapy: The final radiation-induce thrombosis study analysis.","volume":"11","author":"E Daguenet","year":"2022 Apr 24","journal-title":"Cancer Med."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"76-78","DOI":"10.5114\/jcb.2015.48580","article-title":"Thromboembolic events following brachytherapy.","volume":"1","author":"J Guy","year":"2015","journal-title":"J Contemp Brachytherapy."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"73-79","DOI":"10.1038\/sj.bjc.6605463","article-title":"Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery.","volume":"102","author":"M Byrne","year":"2010 Jan 1","journal-title":"Br. J. Cancer."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"153-161","DOI":"10.1177\/1358863X14568705","article-title":"Approach to chemotherapy-associated thrombosis.","volume":"20","author":"P Oppelt","year":"2015 Apr 1","journal-title":"Vasc. Med."},{"key":"ref67","doi-asserted-by":"crossref","first-page":"608-612","DOI":"10.1046\/j.1365-2125.1998.00733.x","article-title":"Tamoxifen and risk of idiopathic venous thromboembolism.","volume":"45","author":"C Meier","year":"1998 Jun 4","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1321-1329","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous Thromboembolism Risk in Patients With Cancer Receiving Chemotherapy: A Real-World Analysis.","volume":"18","author":"G Lyman","year":"2013 Dec 1","journal-title":"Oncologist."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"209-249","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.","volume":"71","author":"H Sung","year":"2021 May 4","journal-title":"CA Cancer J. Clin."},{"key":"ref70","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019373","article-title":"Acute Hospital Mortality of Venous Thromboembolism in Patients With Cancer From Registry Data.","volume":"10","author":"Y Okushi","year":"2021 Jun","journal-title":"J. Am. Heart Assoc."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers.","volume":"166","author":"H Chew","year":"2006 Feb 27","journal-title":"Arch. Intern. Med."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"e1001155","DOI":"10.1371\/journal.pmed.1001155","article-title":"Long-Term Survival in a Large Cohort of Patients with Venous Thrombosis: Incidence and Predictors.","volume":"9","author":"L Flinterman","year":"2012 Jan 10","journal-title":"PLoS Med."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"642-648","DOI":"10.1136\/pgmj.2006.046987","article-title":"Venous thromboembolic disease and cancer.","volume":"82","author":"A Fennerty","year":"2006 Oct 1","journal-title":"Postgrad. Med. J."},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.22838087.v1","article-title":"Raw Data - The Factors Affecting the Survivability of Malignant Cancer Patients with Deep Vein Thrombosis among Subjects with Gynecologic and Non Gynecologic Cancer An Ambispective Cohort Study.sav. figshare.","author":"A Rachman","year":"2023","journal-title":"Journal Contribution."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/12-890\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/12-890\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/12-890\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T01:00:19Z","timestamp":1730163619000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/12-890\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":74,"URL":"https:\/\/doi.org\/10.12688\/f1000research.135252.2","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/f1000research.135252.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.155831.r328897","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.155831.r305997","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.155831.r305997","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.155831.r328897","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/12-890\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.148362.r195071, Susanna Hutajulu, Juan Wiranata, Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Dr Sardjito General Hospital,, Universitas Gadjah Mada, Yogyakarta, Special Region of Yogyakarta, 01 Sep 2023, version 1, 1 approved","URL":"https:\/\/f1000research.com\/articles\/12-890\/v1#referee-response-195071","order":0,"name":"referee-response-195071","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Andhika Rachman<\/b>; \n<i>Posted: 08 Sep 2023<\/i>; \n<b>Response To The Reviewer:<\/b>  Dear Dr. Susanna Hutajulu, We would like to thank you for your time and consideration in handling our manuscript.  Sincerely, Andhika Rachman, MD, PhD Medical staff, Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital  This study aimed to analyze the factors influencing the short-term survival (3 months) of cancer patients with DVT, particularly among those with gynecologic and non-gynecologic cancers. Employing an ambispective cohort study design, a total of 223 cancer patients diagnosed with DVT via Doppler ultrasound were included in this study.  The findings revealed that, across the entire cohort, survival time was notably reduced among subjects who experienced immobilization, were at advanced cancer stages, or developed infections. Within the gynecologic cancer subgroup, survival time was significantly lower in individuals who experienced immobilization and infection. Conversely, within the non-gynecologic cancer subgroup, survival time exhibited a significant decline in subjects who faced immobilization, infection, cancer-related surgeries, and high-risk systemic therapy for DVT.  This study presents novel evidence for the local population, underscoring the significance of both preventing and managing DVT in cancer patients.  There are certain concerns that the authors might need to take into consideration:  \n<b>1. <\/b>The method section of abstract is not so clear. I\u2019m sure it needs brief details of methods applied in the study.\u2028&nbsp;  \n<b>Response:<\/b> Thank you for your constructive comment. We have added more details on the method section of the abstract.  Methods:\n<b> <\/b>An ambispective cohort study was conducted among gynecologic and non-gynecologic cancer patients with DVT, from January 2011 until August 2013. All subjects were observed for three months. The presence of DVT was confirmed using Doppler ultrasound. The analysis was performed using Kaplan-Meier survival analysis. The statistical significance was determined using the log-rank\/Mantel-Cox test.  \n<b>2. <\/b>The content within the second and third paragraphs of the results section, which elucidates the classification of DVT risk based on the chemotherapy regimen and provides an explanation of the Wells score, would be better placed within the method section. This relocation would contribute to a comprehensive depiction of the operational definition of the variables.\u2028&nbsp;  \n<b>Response:<\/b> We have relocated the second and third paragraphs of the results section into the method section.  Wells score has been utilized for over a decade and has predictive value in determining DVT risk in patients who are hospitalized. \n<sup>22<\/sup>\n<sup> ,<\/sup> \n<sup>42<\/sup>\n<sup> <\/sup>We divided the Wells score into two categories: subjects with &lt;3 points were considered to have a low probability of developing DVT, whereas subjects with \u22653 points were considered to have a high probability of developing DVT. Subjects who received tamoxifen, aromatase inhibitors, thalidomide, lenalidomide, bevacizumab, cisplatin, nitrogen mustard, or anthracycline were considered as high-risk systemic therapy for developing DVT. \n<sup>1<\/sup>\n<sup> ,<\/sup> \n<sup>26<\/sup>\n<sup> \u2013<\/sup> \n<sup>41<\/sup>Subjects who did not receive high-risk systemic therapy other than those mentioned above were considered low-risk for developing DVT.  \n<b>3.&nbsp;<\/b>Proportion of radiotherapy utilization can be incorporated into Table 1, as this aspect has not yet been delineated within the existing presentation of the table.\u2028&nbsp;  \n<b>Response:<\/b> We have added the proportion of radiotherapy utilization into Table 1.  \n<b>4.&nbsp;<\/b>To enhance clarity, it would be better to add the &quot;number at risk&quot; and &quot;number censored&quot; below each individual point segment of the survival curve.  \n<b>Response:<\/b> Thank you for your valuable advice. We have added the \u201cnumber at risk\u201d below each individual point segment of the survival curve.  Thank you for your attention. We are eagerly awaiting your response.","URL":"https:\/\/f1000research.com\/articles\/12-890\/v2#referee-comment-10204","order":1,"name":"referee-comment-10204","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.155831.r305997, Hanno Riess, Charite - Universitatmedizin Berlin, Berlin, 29 Aug 2024, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/12-890\/v2#referee-response-305997","order":2,"name":"referee-response-305997","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.155831.r328897, Budi Setiawan, Dr. Kariadi General Hospital, Semarang, 29 Oct 2024, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/12-890\/v2#referee-response-328897","order":3,"name":"referee-response-328897","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":4,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}